Agios Pharmaceuticals (AGIO) Amortization of Deferred Charges (2021 - 2026)

Agios Pharmaceuticals' Amortization of Deferred Charges history runs 6 years deep, the most recent figure standing at $3.3 million for Q1 2026.

• Quarterly Amortization of Deferred Charges rose 7.95% year-over-year to $3.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.7 million (up 7.83% YoY) and the FY2025 annual result came in at $12.4 million, up 7.76% from the prior year.
• Amortization of Deferred Charges was $3.3 million for Q1 2026 at Agios Pharmaceuticals, up from $3.2 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $3.3 million in Q1 2026 and bottomed at $2.4 million in Q1 2022.
• A 5-year average of $2.8 million and a median of $2.8 million in 2024 frame the typical range for Amortization of Deferred Charges.
• Annual changes were most pronounced in 2022 — Amortization of Deferred Charges climbed 0.79% — and 2026, when it advanced 7.95%.
• Agios Pharmaceuticals' Amortization of Deferred Charges stood at $2.6 million in 2022, then gained by 7.41% to $2.8 million in 2023, then grew by 7.59% to $3.0 million in 2024, then climbed by 7.9% to $3.2 million in 2025, then rose by 1.94% to $3.3 million in 2026.
• Business Quant data shows AGIO's Amortization of Deferred Charges at $3.3 million in Q1 2026, $3.2 million in Q4 2025, and $3.1 million in Q3 2025.